{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:29:09Z","timestamp":1783103349783,"version":"3.54.6"},"reference-count":17,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":205,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To compare the efficacy and safety of new insulin glargine 300 units\/mL (Gla-300) with glargine 100 units\/mL (Gla-100) in people with type 2 diabetes using basal insulin (\u226542 units\/day) plus oral antihyperglycemic drugs (OADs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>EDITION 2 was a multicenter, open-label, two-arm study. Adults receiving basal insulin plus OADs were randomized to Gla-300 or Gla-100 once daily for 6 months. The primary end point was change in HbA1c. The main secondary end point was percentage of participants with one or more nocturnal confirmed (\u22643.9 mmol\/L [\u226470 mg\/dL]) or severe hypoglycemic events from week 9 to month 6.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Randomized participants (n = 811) had a mean (SD) HbA1c of 8.24% (0.82) and BMI of 34.8 kg\/m2 (6.4). Glycemic control improved similarly with both basal insulins; least squares mean (SD) reduction from baseline was \u22120.57% (0.09) for Gla-300 and \u22120.56% (0.09) for Gla-100 (mean difference \u22120.01% [95% CI \u22120.14 to 0.12]), with 10% higher dose of Gla-300. Less nocturnal confirmed (\u22643.9 mmol\/L [\u226470 mg\/dL]) or severe hypoglycemia was observed with Gla-300 from week 9 to month 6 (relative risk 0.77 [95% CI 0.61\u20130.99]; P = 0.038) and during the first 8 weeks. Fewer nocturnal and any time (24 h) hypoglycemic events were reported during the entire 6-month period. Weight gain was lower with Gla-300 than with Gla-100 (P = 0.015). No between-treatment differences in safety parameters were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Gla-300 was as effective as Gla-100 and associated with a lower risk of hypoglycemia during the night and at any time of the day.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc14-0990","type":"journal-article","created":{"date-parts":[[2014,9,6]],"date-time":"2014-09-06T07:24:46Z","timestamp":1409988286000},"page":"3235-3243","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":251,"title":["New Insulin Glargine 300 Units\/mL Versus Glargine 100 Units\/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)"],"prefix":"10.2337","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01499095","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hannele","family":"Yki-J\u00e4rvinen","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Helsinki, and Minerva Foundation Institute for Medical Research, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bergenstal","sequence":"additional","affiliation":[{"name":"International Diabetes Center at Park Nicollet, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ziemen","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Wardecki","sequence":"additional","affiliation":[{"name":"Sanofi, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Muehlen-Bartmer","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Boelle","sequence":"additional","affiliation":[{"name":"Sanofi, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Riddle","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,11,8]]},"reference":[{"key":"2022031220321561900_B1","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031220321561900_B2","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1089\/dia.2011.0039","article-title":"Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era","volume":"13","author":"Bolli","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"2022031220321561900_B3","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","article-title":"Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial","volume":"371","author":"Bretzel","year":"2008","journal-title":"Lancet"},{"key":"2022031220321561900_B4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031220321561900_B5","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.2337\/dc12-2238","article-title":"Characteristics associated with maintenance of mean A1C&lt;6.5% in people with dysglycemia in the ORIGIN trial","volume":"36","author":"ORIGIN Trial Investigators","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031220321561900_B6","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/S0140-6736(12)60439-5","article-title":"Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial","volume":"379","author":"Aschner","year":"2012","journal-title":"Lancet"},{"key":"2022031220321561900_B7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabet Med"},{"key":"2022031220321561900_B8","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2337\/diacare.28.10.2543","article-title":"Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem","volume":"28","author":"Polonsky","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031220321561900_B9","article-title":"New insulin glargine 300 units\u22c5mL\u22121 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units\u22c5mL\u22121","author":"Becker","journal-title":"Diabetes Care"},{"key":"2022031220321561900_B10","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2337\/dc14-0991","article-title":"New insulin glargine 300 Units\/mL versus glargine 100 Units\/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)","volume":"37","author":"Riddle","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031220321561900_B11"},{"key":"2022031220321561900_B12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"2022031220321561900_B13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","article-title":"Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia","volume":"28","author":"Workgroup on Hypoglycemia, American Diabetes Association","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031220321561900_B14","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031220321561900_B15","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.2337\/dc12-0060","article-title":"A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes","volume":"35","author":"Bergenstal","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031220321561900_B16","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1038\/sj.ijo.0802746","article-title":"Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir","volume":"28","author":"Kurtzhals","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2022031220321561900_B17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/14656566.7.3.325","article-title":"Insulin detemir: from concept to clinical experience","volume":"7","author":"Home","year":"2006","journal-title":"Expert Opin Pharmacother"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/12\/3235\/619344\/3235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/12\/3235\/619344\/3235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T22:34:30Z","timestamp":1647124470000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/12\/3235\/29207\/New-Insulin-Glargine-300-Units-mL-Versus-Glargine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,8]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,11,8]]},"published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc14-0990","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,8]]}}}